Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exploring the molecular pathways of the activation process in PPARγ recurrent bladder cancer mutants.

The Journal of chemical physics - 28 Oct 2024

de Oliveira Vinícius M, Malospirito Caique C, da Silva Fernando B, Videira Natália B, Dias Marieli M G, Sanches Murilo N, Leite Vitor B P, Figueira Ana Carolina M

Abstract excerpt

The intricate involvement of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) in glucose homeostasis and adipogenesis is well-established. However, its role in cancer, particularly luminal bladder cancer, remains debated. The overexpression and activation of PPARγ are implicated in tumorigenesis. Specific gain-of-function mutations (M280I, I290M, and T475M) within the ligand-binding domain of PPARγ are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gain of Function Mutation
Share to Molecular Dynamics Simulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to PPAR gamma

Share to Urinary Bladder Neoplasms

Source

Identifiers

PMID: 39440760
DOI: 10.1063/5.0232041

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exploring the molecular pathways of the activation process in PPARγ recurrent bladder cancer mutants.PMID 39440760Read ↗

A simple and robust reporter-based framework for deep functional characterization of PPARγ mutants.Semantic proximity Read ↗

Discovery and characterization of FX-909, a covalent inverse agonist of PPARG rationally designed to impose a powerful repressive bias in PPARG for the treatment of PPARG/RXRA-activated muscle-invasive urothelial cancersSemantic proximity Read ↗

Single-Nucleotide Polymorphism of PPARγ, a Protein at the Crossroads of Physiological and Pathological Processes.Semantic proximity Read ↗

Bladder-cancer-associated mutations in RXRA activate peroxisome proliferator-activated receptors to drive urothelial proliferation.Semantic proximity Read ↗

Unveiling clinically significant PPARγ mutations for thiazolidinedione treatment responsiveness through atomistic simulations.Semantic proximity Read ↗

Rational discovery of a novel interface for a coactivator in the peroxisome proliferator-activated receptor gamma: theoretical implications of impairment in type 2 diabetes mellitus.Semantic proximity Read ↗

Investigating the structure and dynamics of the PIK3CA wild-type and H1047R oncogenic mutant.Semantic proximity Read ↗

Natural helix 9 mutants of PPARγ differently affect its transcriptional activitySemantic proximity Read ↗

Defining the Energetic Basis for a Conformational Switch Mediating Ligand-Independent Activation of Mutant Estrogen Receptors in Breast Cancer.Semantic proximity Read ↗

Structural and energetic differences between the human RXRα–PPARγ heterodimer with and without DNA bindingSemantic proximity Read ↗

Structural basis of the transactivation deficiency of the human PPARγ F360L mutant associated with familial partial lipodystrophy.Semantic proximity Read ↗

Bidirectional, iterative approach to the structural delineation of the functional "chemoprint" in GPR40 for agonist recognition.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.